

**Table SI. Patients' characteristics at baseline**

	Total	DLQI <6 at baseline	DLQI ≥6 at baseline	Significance
Total, % (n)	100.0 (46)	41.3 (19)	58.7 (27)	
Sex, % (n)				
Men	26.1 (12)	26.3 (5)	25.9 (7)	0.98 <sup>a</sup>
Women	73.9 (34)	73.7 (14)	74.1 (20)	
Age, years, mean (SD)	45.4 (15.0)	48.8 (14.1)	43.0 (15.4)	0.20 <sup>b</sup>
Median	49	55	47	
Clinical diagnosis, % (n)				
Hand eczema	52.2 (24)	57.9 (11)	48.1 (13)	0.52 <sup>a</sup>
Atopic dermatitis	47.8 (22)	42.1 (8)	51.9 (14)	
Previous atopic dermatitis, % (n)				
Yes	76.1 (35)	63.1 (12)	85.2 (23)	0.23 <sup>c</sup>
No	19.6 (9)	31.6 (6)	11.1 (3)	
Do not know	4.3 (2)	5.3 (1)	3.7 (1)	
Investigator's Global Assessment, % (n)				
Clear	21.7 (10)	47.4 (9)	3.7 (1)	<b>&lt;0.001</b> <sup>c, d</sup>
Almost clear	26.1 (12)	36.8 (7)	18.5 (5)	
Moderate	26.1 (12)	10.5 (2)	37.0 (10)	
Severe	26.1 (12)	5.3 (1)	40.7 (11)	
Previous eczema treatment, % (n)				
Local <sup>e</sup>	43.5 (20)	52.6 (10)	37.0 (10)	0.55 <sup>c</sup>
Light therapy	34.8 (16)	31.6 (6)	37.0 (10)	
Systematic therapy <sup>f</sup>	21.7 (10)	15.8 (3)	25.9 (7)	
Dermatology clinic, % (n)				
Örebro	45.7 (21)	47.4 (9)	44.4 (12)	0.85 <sup>a</sup>
Eskilstuna	54.3 (25)	52.6 (10)	55.6 (15)	

<sup>a</sup> $\chi^2$  test. <sup>b</sup>Student's *t*-test. <sup>c</sup>Exact test. <sup>d</sup>Post-hoc testing using adjusted standardized residuals >2 in the cell provides evidence against the null hypothesis. Adjusted standardized residuals >2 in "almost clear" and "severe" cells. <sup>e</sup>Topical corticosteroid and/or moisturizers. <sup>f</sup>Alitretinoin, azathioprine, cyclosporine, methotrexate or prednisolone. Dermatology Life Quality Index (DLQI) <6 corresponds to no-to-small effect on patients' QoL. DLQI ≥6 corresponds to moderate-to-extreme effect on patients' quality of life. SD: standard deviation. Significance in bold text.